Very high response rates and improved survival have been noted with the administration of the type I BRAF inhibitor vemurafenib (formerly PLX4032/RG7204) to patients with BRAFV600E mutant cutaneous metastatic melanoma [11-13]. The gene discussed is BRAF; the disease is metastatic melanoma.